共 13 条
- [8] Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36 [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2022, 46 : 135 - 136
- [9] Re: Meelan Bul, Xiaoye Zhu, Antti Rannikko, et al. Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.02.002 [J]. EUROPEAN UROLOGY, 2012, 62 (01) : E9 - E9
- [10] Re: Ola Bratt, Erik Holmberg, Ove Andren, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol 2019;76:461-6 [J]. EUROPEAN UROLOGY, 2020, 77 (05) : E136 - E136